Lonza Group announces extension of the microbial fermentation plant in Kourim
Production of highly potent active ingredients
Therefore a further fermentation line with a capacity of 2 x 15m3 will be constructed. This new plant will enable Lonza to cope with the increasing demand for these ingredients for the Life Sciences Industry. The extension will include special containments to safely handle such potent intermediates and active ingredients. The plant will be operational in the second half of 2003.
Lonza Biotec is focused on microbial fermentation and is the leader in process development and custom manufacturing of therapeutic ingredients and intermediates based on its 20 years of experience. Lonza Biotec undertakes manufacturing services for the pharmaceutical, biotechnology and nutrition industries. With headquarters in Basel (Switzerland), Lonza Biotec operates R&D and cGMP multi-product manufacturing facilities in Visp (Switzerland) and Kourim (Czech Republic).
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.